Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryKaiser Permanente Epilepsy Coverage Update | OpenP…
    Ask Trek AI about this page
    ModifiedKaiser PermanentePolicy N/A

    Clinical Review Criteria Procedural Treatments for Epilepsy

    Customize your policy alerts

    Sign up for all Kaiser Permanente policy alerts

    Know when Kaiser Permanente releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical necessity and coverage criteria for non-invasive and implantable vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation for epilepsy and other listed indications for Medicare and non-Medicare members in Washington.

    Policy Summary
    PayerKaiser Permanente
    PolicyClinical Review Criteria Procedural Treatments for Epilepsy
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionSend all deep brain stimulation for epilepsy cases to a medical director for review under the non-Medicare criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Clinical criteria for deep brain stimulation as adjunctive treatment for adults with refractory focal epilepsy were approved.

    Clinical criteria for Responsive Neurostimulation using the NeuroPace system were adopted.

    A medical technology assessment review for the gammaCore Sapphire non-invasive vagus nerve stimulator was added.

    Applicable procedure codes were updated.

    Clinical criteria were added for deep brain stimulation as adjunctive treatment for adults with refractory focal epilepsy who are not candidates for other surgical options.

    Applicable procedure codes were updated in the revision history.

    Clinical criteria for responsive neurostimulation were added in a prior revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+Minimum age for deep brain stimulation and responsive neurostimulation
    ≥3/monthRequired disabling seizure frequency
    ≥2Antiepileptic medication failures required
    Not coveredNon-invasive vagus nerve stimulation
    11/01/2026Approved DBS criteria effective date

    Medical Necessity and Coverage Criteria

    Deep Brain Stimulation for Epilepsy

    For non-Medicare members, deep brain stimulation for epilepsy is considered medically necessary when ALL of the following criteria are met. Effective until November 1, 2026; send all cases to an MD for review.

    ALL of the following

    • Individual is 18 years or older.
    • Device is FDA approved (PMA or 510(k) only).
    • Diagnosis of partial-onset seizures, such as motor focal seizures, complex focal seizures, or secondary generalized seizures.
    • Average of 3 or more disabling partial-onset seizures per month for 3 consecutive months, excluding spells, cardiogenic syncope, and other non-epileptiform seizures, if present.>= 3 disabling partial-onset seizures/month for 3 consecutive months
    • Diagnostic testing identified no more than 2 epileptogenic foci.<= 2 epileptogenic foci
    • Failed 2 or more antiepileptic medications.>= 2 antiepileptic medications
    • Failure of, contraindication to, or not a candidate for at least one of the following other surgical treatments for epilepsy

      • Focal resective epilepsy surgery, including when the epileptic focus is near eloquent cerebral cortex or when the individual has bilateral temporal epilepsy.
      • Vagus nerve stimulation.

    Replacement or revision

    • The individual meets ALL of the deep brain stimulation medical-necessity criteria above.
    • The existing neurostimulator, lead, or monitor is no longer under warranty and cannot be repaired.
    • Replacement or revision involves the deep brain stimulator, battery, leads, and/or monitor.

    Implantable Vagus Nerve Stimulator

    Coverage criteria for an implantable vagus nerve stimulator are indication-based.

    Applicable indication

    • Adjunctive treatment for epilepsy: no medical-necessity review is required for this service.
    • Mental health diagnosis: not covered under MCG B-821-T, Vagus Nerve Stimulation, Implantable: Behavioral Health Care.
    • Any other non-mental-health diagnosis: not covered under MCG A-0424, Vagus Nerve Stimulation—Implantable; the service is not covered for diagnoses besides epilepsy.

    Responsive Neurostimulation

    Responsive neurostimulation is considered medically necessary as adjunctive therapy for patients with focal epilepsy when ALL of the following criteria are met.

    ALL of the following

    • Individual is 18 years or older.
    • Device is FDA approved (PMA or 510(k) only).
    • Diagnosis of partial-onset seizures, such as motor focal seizures, complex focal seizures, or secondary generalized seizures.
    • Average of 3 or more disabling partial-onset seizures per month for 3 consecutive months, excluding spells, cardiogenic syncope, and other non-epileptiform seizures, if present.>= 3 disabling partial-onset seizures/month for 3 consecutive months

    Implantable Vagus Nerve Stimulation — Policy Statement

    Implantable vagus nerve stimulation is considered medically necessary when the applicable policy-statement criteria are met.

    Applicable policy statement

    • Adjunctive treatment for epilepsy; no medical-necessity review is required.
    • Mental health diagnoses are not covered under MCG B-821-T.
    • All other non-mental-health diagnoses are not covered under MCG A-0424; coverage does not apply to diagnoses besides epilepsy.

    Responsive Neurostimulation — Policy Statement

    Responsive neurostimulation is considered medically necessary when the applicable policy-statement criteria are met.

    Applicable policy-statement criteria

    • Individual is 18 years or older.
    • Device is FDA approved (PMA or 510(k) only).
    • Diagnosis is focal or partial-onset epilepsy, including motor focal, complex focal, or secondary generalized seizures.
    • Average of 3 or more disabling partial-onset seizures per month for 3 consecutive months, excluding non-epileptiform events.
    • Diagnostic testing identified no more than 2 epileptogenic foci.

    Deep Brain Stimulation for Refractory Epilepsy — MTAC Determination

    The Kaiser Permanente Medical Technology Assessment Criteria determination supports the use of deep brain stimulation for patients with refractory epilepsy.

    MTAC determination

    • The use of a deep brain stimulator for patients with refractory epilepsy meets the Kaiser Permanente Medical Technology Assessment Criteria.
    • The determination is based on low-certainty evidence that anterior thalamic nucleus deep brain stimulation may reduce seizure frequency and appears safe over the long term in adults with refractory focal-onset epilepsy.

    Transcutaneous Vagus Nerve Stimulation

    Transcutaneous vagus nerve stimulation is not medically necessary.

    Not medically necessary

    • Transcutaneous vagus nerve stimulation, including the gammaCore Sapphire non-invasive vagus nerve stimulator, is considered not medically necessary.

    Non-invasive vagus nerve stimulation, including gammaCore Sapphire, is not covered under MCG A-0998, Vagus Nerve Stimulation—Transcutaneous.

    Implantable vagus nerve stimulation is not covered for mental health diagnoses under MCG B-821-T or for non-epilepsy diagnoses under MCG A-0424. Adjunctive treatment for epilepsy does not require medical-necessity review.

    Responsive neurostimulation is investigational for focal epilepsy when the applicable medical-necessity criteria are not met.

    Responsive neurostimulation placement is contraindicated or excluded for individuals with 3 or more specific seizure foci, primary generalized epilepsy, or a rapidly progressive neurologic disorder.

    Transcutaneous gammaCore Sapphire non-invasive vagus nerve stimulation is considered not medically necessary.

    Responsive neurostimulation is investigational for indications outside qualifying focal epilepsy, including other indications not meeting the stated criteria.

    Deep brain stimulation is not medically necessary when the required criteria are not satisfied. For all other indications, refer to the Deep Brain Stimulator clinical criteria.

    The use of vagus nerve stimulation for treatment-resistant depression does not meet the Kaiser Permanente Medical Technology Assessment Criteria. The evidence was insufficient to establish effectiveness, including a negative randomized controlled trial and subsequent low-grade or methodologically limited evidence.

    Transcutaneous gammaCore Sapphire non-invasive vagus nerve stimulation is considered not medically necessary.

    Codes and Coverage Parameters

    Referenced Medicare coverage manual sectionsmixed
    160.18Vagus Nerve Stimulation
    160.7Electrical Nerve Stimulators
    160.2Treatment of Motor Function Disorders with Electric Nerve Stimulation
    160.24Deep Brain Stimulation for Essential Tremor and Parkinson's Disease
    Referenced MCG guideline identifiersmixed
    A-0998Vagus Nerve Stimulation- Transcutaneous
    B-821-TVagus Nerve Stimulation, Implantable: Behavioral Health Care
    A-0424Vagus Nerve Stimulation - Implantable
    Vagus Nerve Stimulation, Implantable — medically necessary when applicable policy criteria are metCPTCovered
    61885Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
    61888Revision or removal of cranial neurostimulator pulse generator or receiver.
    64553Percutaneous implantation of neurostimulator electrode array; cranial nerve.
    64568Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
    64569Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator.
    Vagus Nerve Stimulation, Transcutaneous (gammaCore Sapphire non-invasive vagus nerve stimulator)HCPCSNot Covered
    E0735Vagus nerve stimulator [non-invasive].
    E1399Durable medical equipment, miscellaneous.
    Responsive Neurostimulation (RNS) — medically necessary when applicable policy criteria are metCPTCovered
    61850Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical.
    61860Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical.
    61863Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in a subcortical site; first array.
    61891Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s).
    61892Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed.
    61880Revision or removal of intracranial neurostimulator electrodes.
    Minimum age
    Minimum age18 years or older
    Deep brain stimulationApplies to adults meeting the applicable epilepsy criteria
    Responsive neurostimulationApplies to adults meeting the applicable focal-epilepsy criteria
    Disabling partial-onset seizure frequency
    Required frequencyAverage of 3 or more disabling partial-onset seizures per month
    Required durationFor 3 consecutive months

    Authorization and Documentation Requirements

    Prior Authorization

    Medical-Director Review Required for DBS

    For non-Medicare members, send all deep brain stimulation (DBS) cases for epilepsy to a medical director for review. This requirement is effective until November 1, 2026.

    • Applies to DBS for epilepsy in non-Medicare members.
    • Submit all cases for physician review before authorization.
    Documentation Required

    Other Epilepsy Treatments Must Be Unsuccessful or Unsuitable

    Document that other surgical treatments for epilepsy have failed, are contraindicated, or are unsuitable before approving DBS or responsive neurostimulation (RNS).

    • Address focal resective epilepsy surgery, including situations such as an epileptic focus near eloquent cortex or bilateral temporal epilepsy.
    • Address vagus nerve stimulation as another surgical treatment option.

    Clinical Background

    Epilepsy is generally treated first with antiepileptic medications. For selected patients, treatment may include surgical resection of the epileptic focus or neurostimulation. The policy addresses implanted vagus nerve stimulation as adjunctive treatment for medically refractory partial-onset seizures, as well as deep brain stimulation and responsive neurostimulation for selected adults with focal epilepsy who continue to have disabling seizures despite medication and are not candidates for other surgical treatments.

    Key Terms

    Partial-onset seizures
    Core definitionSeizures arising from a localized epileptogenic region
    Included typeMotor focal seizures
    Included typeComplex focal seizures
    Included typeSecondary generalized seizures
    FDA-approved device
    DefinitionA device approved by the U.S. Food and Drug Administration
    Approval pathwayPremarket Approval (PMA)
    Policy Summary
    PayerKaiser Permanente
    PolicyClinical Review Criteria Procedural Treatments for Epilepsy
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionSend all deep brain stimulation for epilepsy cases to a medical director for review under the non-Medicare criteria.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCodes and Coverage ParametersAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    Diagnostic testing identified no more than 2 epileptogenic foci.
    <= 2 epileptogenic foci
  1. Failed 2 or more antiepileptic medications.>= 2 antiepileptic medications
  2. Failure of, contraindication to, or not a candidate for at least one of the following other surgical treatments for epilepsy

    • Focal resective epilepsy surgery, including when the epileptic focus is near eloquent cerebral cortex or when the individual has bilateral temporal epilepsy.
    • Vagus nerve stimulation.
  3. Replacement or revision

    • The individual meets ALL of the responsive-neurostimulation medical-necessity criteria above.
    • The existing responsive cortical stimulation neurostimulator, battery, leads, and/or monitor is no longer under warranty and cannot be repaired.
    • Replacement or revision involves the responsive cortical stimulation neurostimulator, battery, leads, and/or monitor.
    Failed 2 or more antiepileptic medications.
  4. Failure of, contraindication to, or not a candidate for focal resective epilepsy surgery and/or vagus nerve stimulation.
  5. No contraindication to responsive neurostimulation device placement, including 3 or more specific seizure foci, primary generalized epilepsy, or a rapidly progressive neurologic disorder.
  6. Excluded eventsSpells, cardiogenic syncope, and other non-epileptiform seizures are excluded when present
    Epileptogenic foci
    Maximum number of fociNo more than 2 epileptogenic foci
    Identification methodMust be identified by diagnostic testing
    Responsive neurostimulation contraindicationThree or more specific seizure foci are a contraindication to responsive neurostimulation device placement
    Failed antiepileptic medications
    Minimum medication failuresGreater than or equal to 2 antiepileptic medications
    Applies toDeep brain stimulation and responsive neurostimulation criteria
    Treatment historyThe individual must have failed the required antiepileptic medications
    Documentation Required

    Document Antiepileptic Medication Failures

    Document failure of at least two antiepileptic medications for DBS or RNS eligibility.

    • The criteria require failure of greater than or equal to two antiepileptic medications.
    Documentation Required

    Document Epilepsy Treatment History and Eligibility

    For DBS or RNS, document the complete epilepsy treatment history and each eligibility criterion, including age, FDA device approval, seizure diagnosis and frequency, epileptogenic foci, and medication history.

    • Individual must be 18 years or older.
    • Device must be FDA approved through a PMA or 510(k).
    • Diagnosis must be partial-onset seizures, such as motor focal, complex focal, or secondary generalized seizures.
    • Average of at least 3 disabling partial-onset seizures per month for 3 consecutive months is required, excluding non-epileptiform events.
    • Diagnostic testing must identify no more than 2 epileptogenic foci.
    • For RNS, document absence of 3 or more specific seizure foci, primary generalized epilepsy, and a rapidly progressive neurologic disorder.
    Documentation Required

    Document Replacement or Revision Rationale

    For replacement or revision of a DBS or RNS neurostimulator, battery, leads, or monitor, document that the original medical-necessity criteria remain satisfied and that the existing device is no longer under warranty and cannot be repaired.

    • Replacement or revision is not justified solely because the device requires service.
    • Include documentation supporting continued eligibility under all applicable initial criteria.
    Denial Risk

    Non-Invasive VNS Is Not Covered

    Non-invasive vagus nerve stimulation, including the gammaCore Sapphire device, is not covered under the cited MCG guidance and is considered not medically necessary.

    • Cited guidance: MCG A-0998, Vagus Nerve Stimulation—Transcutaneous.
    • Referenced codes include HCPCS E0735 and E1399.
    Denial Risk

    Mental Health Indication Excluded

    Implantable vagus nerve stimulation for mental health diagnoses is not covered under the cited MCG guidance.

    • Cited guidance: MCG B-821-T, Vagus Nerve Stimulation, Implantable: Behavioral Health Care.
    • The exclusion applies to implantable VNS for mental health diagnoses.
    Denial Risk

    Unsupported Indication

    Implantable VNS is not supported for diagnoses other than epilepsy, and RNS is not supported for indications outside the qualifying criteria. RNS is investigational for other indications, including focal epilepsy that does not meet the stated requirements.

    • Cited guidance for implantable VNS: MCG A-0424, Vagus Nerve Stimulation—Implantable.
    • Do not treat an unsupported diagnosis or an unqualified epilepsy indication as medically necessary.
    Denial Risk

    Failure to Meet Medical Necessity Criteria

    Deny or do not authorize DBS or RNS when medical-necessity criteria are not met. Verify age, seizure type and frequency, medication failures, number of epileptogenic foci, device approval, surgical-treatment suitability, and applicable contraindications.

    • Unmet requirements include being under age 18, lacking an FDA-approved device, having fewer than 3 disabling partial-onset seizures per month for 3 consecutive months, or having more than 2 epileptogenic foci.
    • For RNS, contraindications include 3 or more specific seizure foci, primary generalized epilepsy, or a rapidly progressive neurologic disorder.
    • Failure of at least 2 antiepileptic medications and failure, contraindication, or unsuitability of other surgical treatments must be documented.
    Denial Risk

    GammaCore Sapphire Is Not Medically Necessary

    Non-invasive vagus nerve stimulation with gammaCore Sapphire is considered not medically necessary and should not be authorized for coverage.

    • Device identified as a non-invasive vagus nerve stimulator.
    • Referenced codes include HCPCS E0735 and E1399.
    Denial Risk

    VNS for Treatment-Resistant Depression Does Not Meet Criteria

    Vagus nerve stimulation for treatment-resistant depression does not meet Kaiser Permanente Medical Technology Assessment Criteria. The cited MTAC review found insufficient evidence of effectiveness, including a negative randomized controlled trial and no adequate comparative evidence establishing benefit.

    • Evidence was limited by manufacturer-linked research, selection and observation bias, and low-quality case-series data.
    • Do not represent VNS for treatment-resistant depression as meeting the cited medical-technology assessment criteria.
    Denial Risk

    RNS Evidence Is Insufficient in Cited Review

    The cited review concluded that evidence is insufficient to support active RNS for focal drug-resistant epilepsy. The available evidence was limited in quality and quantity and did not establish comparative safety or effectiveness versus resective surgery or other neuromodulation therapies.

    • Insufficient evidence exists to determine net health outcomes for RNS in focal drug-resistant epilepsy.
    • The evidence included a single industry-funded sham-controlled randomized trial with only a 3-month randomized period and potential serious adverse events.
    • High-quality studies with longer follow-up are needed to establish comparative effectiveness and safety.
    Alternative approval pathway510(k)
    Responsive neurostimulation
    DefinitionA neurostimulation system used as adjunctive therapy for focal epilepsy
    Detection functionDetects abnormal electrical activity
    Treatment functionDelivers responsive stimulation